Cross-Border Success: Jinxin Fertility’s Revenue Surges 22% Driven by US-China "Dual-Corridor" Strategy
Jinxin Fertility (HK: 1951) released its preliminary FY2025 earnings today, reporting a 22% year-on-year revenue increase. The growth was primarily driven by their "HRC Fertility" US operations, which saw a 40% spike in Chinese patients traveling for PGT-A testing and surrogacy services, now that travel restrictions have fully normalized.
Policy Thaw: Two Chinese Provinces Pilot Oocyte Cryo preservation for Non-Married Women with Medical Indications
Breaking news from the National Health Commission (NHC) briefing this morning: A limited pilot program has been approved for Sichuan and Guangdong.
Guangdong: China’s Top Fertility Hub Records 1 Million+ Births for 6th Consecutive Year
Guangdong Province has maintained its status as China’s top fertility region, surpassing 1 million births in 2025. The province accounts for a massive portion of the nation's young, reproductive-age population, with a "fertility floor" supported by both cultural tradition and the "cross-provincial" marriage registration pilot.
Unexpected Rebound: Marriage Registrations Spike in Late 2025
In a positive counter-trend, new data shows a significant rebound in marriage registrations across major Chinese cities (including Beijing and Shanghai) following the easing of registration regulations in late 2025.
Data Alert: China’s 2025 Births Drop to 7.92 Million – Implication for IVF Demand
Official data released this week confirms China's population declined for the fourth consecutive year, with 2025 births falling to approximately 7.92 million.
Medical Tourism Opportunity: Alpha IVF Group Anticipates Surge in Chinese Patients via Direct Flights
Alpha IVF Group (Malaysia) has announced a positive outlook for FY27, specifically citing expected growth in patient volume from China.